Related Experiment Video
Updated: Aug 8, 2026

07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Primary extremity sarcoma: what is the appropriate follow-up?
B P Whooley1, J F Gibbs, M M Mooney
1Roswell Park Cancer Institute, State University of New York at Buffalo, 14263, USA.
Annals of Surgical Oncology
|February 16, 2000
Summary
Close clinical assessment and chest x-rays effectively detect recurrences in extremity soft tissue sarcoma patients. Laboratory tests were not useful for identifying early signs of cancer recurrence.
Area of Science:
- Oncology
- Sarcoma Research
- Clinical Diagnostics
Background:
- Soft tissue sarcomas are rare cancers affecting extremities.
- Early detection of recurrence is crucial for patient outcomes.
- Effective surveillance strategies are needed for primary extremity soft tissue sarcoma.
Purpose of the Study:
- To evaluate the efficacy of follow-up tests in detecting initial local and distant recurrences.
- To assess the role of clinical examination, laboratory tests, and imaging in sarcoma surveillance.
- To determine the optimal follow-up protocol for patients with extremity soft tissue sarcoma.
Main Methods:
- Retrospective analysis of 174 adult primary extremity soft tissue sarcoma cases (1982-1992).
- Follow-up schedule: every 3-6 months for 4 years, then annually.
- Standard surveillance included history, physical exam, blood tests, chest x-ray; high-grade tumors had annual imaging.
Main Results:
- Local recurrences (29/141) were detected by physical exam; distant recurrences (57/141) often presented with symptoms.
- Chest x-rays detected 30/36 asymptomatic lung recurrences, with high positive (92%) and negative (97%) predictive values.
- Laboratory tests did not lead to any recurrence detection.
Conclusions:
- Clinical assessment and chest x-ray are effective for surveillance in extremity soft tissue sarcoma.
- Intensive follow-up protocols aid in early detection of recurrence.
- Routine laboratory testing is not recommended for detecting sarcoma recurrence.

